Skip to content
ChickenStockChickenStock
ResearchLEGN
Legend Biotech logo

Legend Biotech (LEGN) stock

NASDAQ

$17.40-6.15%(-1.14)

As of the Nov 13, 2026 close (U.S. Eastern)

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 13, 2026 · Financial period · Latest fiscal year

Latest fiscal-year financials · Computed in-house by ChickenStock

P/E

-10.84x

Net loss — not comparable

P/B

3.21x

P/S

3.13x

Latest earnings

SEC filings

Oct–Dec 2025(FY2025 Q4)

Revenue in the latest quarter: $307M.

Key reported figures come first. Select one to see the same quarter across three years.

The fourth-quarter figure is the annual total minus the first three quarters.

See the same quarter across three years →

Filed Mar 10, 2026 · 20-F · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

11 SEC filings
  • Sanders Corazon (Corsee) D.Director · Sep 29, 2026Open-market sale27,370 shares · $259K
    Avg. price $9.4652,731 shares held after
  • Casey Patrick JohnDirector · Sep 24, 2026Grant or award20,986 shares · $0
    Avg. price $069,590 shares held after
  • Mao LiDirector · Sep 24, 2026Grant or award20,986 shares · $0
    Avg. price $065,316 shares held after
  • Salovey PeterDirector · Sep 24, 2026Grant or award28,330 shares · $0
    Avg. price $055,096 shares held after
  • Heyman Tomas J.Director · Sep 24, 2026Grant or award20,986 shares · $0
    Avg. price $053,720 shares held after
  • Ji Darren XiaohuiDirector · Sep 24, 2026Grant or award28,330 shares · $0
    Avg. price $092,103 shares held after
  • Sanders Corazon (Corsee) D.Director · Sep 24, 2026Grant or award20,986 shares · $0
    Avg. price $080,101 shares held after
  • Santos Carlos EChief Financial Officer · Sep 21, 2026Open-market sale5,430 shares · $50K
    Avg. price $9.1414,246 shares held after
  • Santos Carlos EChief Financial Officer · Sep 21, 2026Grant or award19,676 shares · $0
    Avg. price $019,676 shares held after
  • Zhang IngridChief Executive Officer · Sep 15, 2026Grant or award1,131,860 shares · $0
    Avg. price $01,131,860 shares held after
  • BASH ALANInterim CEO · Aug 14, 2026Grant or award4,908 shares · $0
    Avg. price $035,142 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Legend Biotech (LEGN) stock information

NASDAQ

Legend Biotech (LEGN) is listed on NASDAQ. Its market capitalization is about $3.2B. On trailing-twelve-month earnings the P/E ratio is -10.84, and the P/B ratio is 3.21. Return on equity is -29.6%. These figures are computed in-house from official filings and are reference information only.

Legend Biotech — frequently asked questions

What is the P/E ratio of Legend Biotech (LEGN)?
On a trailing-twelve-month basis, LEGN trades at a P/E ratio of -10.84. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Legend Biotech?
LEGN has a market capitalization of about $3.2B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.